Primbol 100mg/ml 10x1ml Ampullen by Raw Pharma

Usage

1. Confirm baseline bloodwork before the first injection: LH, FSH, total testosterone, estradiol (LC-MS/MS), ALAT, ASAT, and haematocrit — this panel benchmarks the combined suppression attributable to both Primbol and the co-administered SARM.
2. Select the SARM partner before opening the first ampoule — LGD-4033 (5–10 mg daily) or Ostarine MK-2866 (12.5–25 mg daily) are the most protocol-documented options with injectable Methenolone Enanthate; start the SARM on the same day as the first Primbol injection.
3. Draw the Primbol dose using a 1 ml syringe: at 100 mg/ml each 0.5 ml graduation equals exactly 50 mg, enabling precise adjustment without recalculation when the SARM dose is simultaneously changed.
4. Inject intramuscularly (gluteal or vastus lateralis) twice weekly on a fixed schedule — a Monday/Thursday split is commonly used — keeping injection volume per site at or below 2 ml for comfort.
5. Take the oral SARM at a consistent time daily, ideally with a meal; do not adjust the SARM dose and the Primbol dose simultaneously — change one variable per four-week assessment period to isolate which agent is driving any observed change.
6. Run repeat bloodwork at weeks four and eight covering the full baseline panel plus HOMA-IR if the SARM selected has documented metabolic interaction; use results to decide whether to extend, taper, or modify dosing before the final cycle week.

Warnings

Frequently asked questions

Can Methenolone Enanthate injectable be combined safely with SARMs in the same cycle?

Yes, the combination is mechanistically compatible. Methenolone Enanthate provides systemic androgen receptor occupancy and HPG suppression management while the SARM layer adds tissue-selective signalling. Because Methenolone does not aromatise, combining it with non-aromatising SARMs keeps estradiol load low throughout the stack, confirmed by LC-MS/MS estrogen assay at weeks four and eight.

Which specific SARMs are most commonly paired with Primobolan injectable in documented protocols?

LGD-4033 at 5–10 mg daily and Ostarine (MK-2866) at 12.5–25 mg daily are the most frequently cited SARM partners for injectable Methenolone Enanthate. Both compounds add lean-mass signalling through tissue-biased AR conformations distinct from Methenolone's full-agonist steroidal binding, making the stack mechanistically additive rather than redundant.

What bloodwork markers should I track when running Primbol alongside a SARM?

LH and FSH via immunoassay at weeks four and eight measure combined HPG suppression depth from both agents. Serum estradiol by LC-MS/MS confirms that Methenolone's non-aromatising profile holds under real-cycle conditions. Total testosterone and haematocrit provide safety margins; ALAT and ASAT flag hepatocellular stress if oral SARMs with known hepatic interaction are co-administered.

Why does the single-dose ampoule format matter specifically in a long SARM combination cycle?

In cycles extending beyond ten weeks — common when SARMs are included for sustained lean-mass accrual — each injection event introduces a sterility variable. Raw Pharma Primbol's 1 ml ampoule format is sealed at production, eliminating the cumulative contamination risk that builds across repeated punctures of a multi-dose vial. The 10-ampoule pack provides a structured ten-week supply at one injection per week or a five-week supply at twice-weekly dosing.

How does Primbol's 100 mg/ml concentration compare to higher-density Methenolone products when dose-adjusting during a SARM stack?

At 100 mg/ml, each 0.5 ml graduation delivers exactly 50 mg — the smallest practical weekly adjustment increment when simultaneously titrating a SARM dose. Higher-density formulations compress volume, which reduces syringe-scale readability for low-dose adjustments. Primbol's 100 mg/ml specification is the lowest available in the injectable Methenolone category, making it the most syringe-precise option for fine-tuned dual-compound titration. (2) angle_used

Manufacturer

Raw Pharma's product portfolio is structured around distinct formulation lines rather than a single monolithic catalogue — Primbol sits within the company's injectable enanthate-ester line, which is differentiated from the shorter-ester and oral lines by container format (single-dose ampoule versus multi-dose vial) and by the quality documentation requirements applied at release. Each line carries its own batch-release checklist: the injectable enanthate series mandates HPLC potency verification against the declared concentration specification and LAL endotoxin assay clearance before a Certificate of Analysis is issued, rather than relying on the same CoA template used for the oral or short-ester injectable products. This line-specific approach to documentation means that Primbol's quality record is maintained separately from other Raw Pharma active ingredients, allowing per-batch traceability without cross-product quality pooling.